Substance / Medication

Trientine

Overview

Active Ingredient
trientine
RxNorm CUI
10798

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
New insights into the effects of dissolution profiles on the pharmacokinetics of trientine dihydrochloride.
Weiss Karl Heinz, Kruse Carlot, Abd-Elaziz Khalid et al. · Eur J Clin Pharmacol · 2025
PMID: 41428007RCT
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky Michael L, Czlonkowska Anna, Zuin Massimo et al. · Lancet Gastroenterol Hepatol · 2022
PMID: 36183738Trial
Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects.
Weiss Karl Heinz, Thompson Catherine, Dogterom Peter et al. · Eur J Drug Metab Pharmacokinet · 2021
PMID: 34357516Trial
The steady state pharmacokinetics of trientine in Wilson disease patients.
Pfeiffenberger Jan, Kruse Carlot, Mutch Peter et al. · Eur J Clin Pharmacol · 2018
PMID: 29417175Trial
Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease.
Ala Aftab, Aliu Ermal, Schilsky Michael L · Dig Dis Sci · 2015
PMID: 25605552TrialFull text (PMC)
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
Fu Siqing, Hou Ming-Mo, Wheler Jennifer et al. · Invest New Drugs · 2014
PMID: 24306314Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Trientine (substance)
SNOMED CT
373456001
UMLS CUI
C0040976
RxNorm CUI
10798

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.